Incretin-based investigational therapies for the treatment of MASLD/MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common form of chronic liver disease. It exists as either simple steatosis or its more progressive form, metabolic dysfunction-associated steatohepatitis (MASH), formerly, non-alcoholic steatohepatitis (NASH). The global prevalence of MASLD is estimated to be 32% among adults and is projected to continue to rise with increasing rates of obesity, type 2 diabetes, and metabolic syndrome. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 16, 2024 Category: Endocrinology Authors: Bram Brouwers, Girish Rao, Yuanyuan Tang, Ángel Rodríguez, Leonard C Glass, Mark L Hartman Source Type: research
Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes
(Source: Journal of Clinical Investigation)
Source: Journal of Clinical Investigation - April 15, 2024 Category: Biomedical Science Authors: Gianfranco Di Giuseppe, Laura Soldovieri, Gea Ciccarelli, Pietro Manuel Ferraro, Giuseppe Quero, Francesca Cinti, Umberto Capece, Simona Moffa, Enrico Celestino Nista, Antonio Gasbarrini, Andrea Mari, Sergio Alfieri, Vincenzo Tondolo, Alfredo Pontecorvi, Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9:S1896-1126(24)00022-1. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The edu...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9;69(1):208-215. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The educational...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Obesity - Standards, trends and advances
Adv Med Sci. 2024 Apr 9;69(1):208-215. doi: 10.1016/j.advms.2024.04.001. Online ahead of print.ABSTRACTObesity continues to be a significant global health concern, giving rise to various complications. This review article explores the current standards and emerging innovations in diagnosing and treating obesity, including recent disease name change, staging system or therapeutic goals. This narrative review has been based on recent scientific articles from PubMed database, limiting the scope of topics to current standards and upcoming developments and breakthroughs in the diagnosis and treatment of obesity. The educational...
Source: Advances in Medical Sciences - April 11, 2024 Category: Biomedical Science Authors: Jakub Go łacki Beata Matyjaszek-Matuszek Source Type: research
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
AbstractThe discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatme...
Source: Diabetes Therapy - April 4, 2024 Category: Endocrinology Source Type: research
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson ’s disease
In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD. (Source: AGE)
Source: AGE - April 2, 2024 Category: Geriatrics Source Type: research
Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae)
Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. Online ahead of print.ABSTRACTFive host-defense peptides (figainin 2PL, hylin PL, raniseptin PL, plasticin PL, and peptide YL) were isolated from norepinephrine-stimulated skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae) collected in Trinidad. Raniseptin PL (GVFDTVKKIGKAVGKFALGVAKNYLNS.NH2) and figainin 2PL (FLGTVLKLGKAIAKTVVPMLTNAMQP KQ.NH2) showed potent and rapid bactericidal activity against a range of clinically relevant Gram-positive and Gram-negative ESKAPE + pathogens and Clostridioides difficile. The...
Source: Biochimie - April 1, 2024 Category: Biochemistry Authors: J Michael Conlon Ananyaa Sridhar Dawood Khan Taylor S Cunning Jack J Delaney Megan G Taggart Nigel G Ternan J érôme Leprince Laurent Coquet Thierry Jouenne Samir Attoub Milena Mechkarska Source Type: research
Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae)
Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. Online ahead of print.ABSTRACTFive host-defense peptides (figainin 2PL, hylin PL, raniseptin PL, plasticin PL, and peptide YL) were isolated from norepinephrine-stimulated skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae) collected in Trinidad. Raniseptin PL (GVFDTVKKIGKAVGKFALGVAKNYLNS.NH2) and figainin 2PL (FLGTVLKLGKAIAKTVVPMLTNAMQP KQ.NH2) showed potent and rapid bactericidal activity against a range of clinically relevant Gram-positive and Gram-negative ESKAPE + pathogens and Clostridioides difficile. The...
Source: Biochimie - April 1, 2024 Category: Biochemistry Authors: J Michael Conlon Ananyaa Sridhar Dawood Khan Taylor S Cunning Jack J Delaney Megan G Taggart Nigel G Ternan J érôme Leprince Laurent Coquet Thierry Jouenne Samir Attoub Milena Mechkarska Source Type: research
Multifunctional host-defense peptides isolated from skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae)
Biochimie. 2024 Mar 30:S0300-9084(24)00070-1. doi: 10.1016/j.biochi.2024.03.012. Online ahead of print.ABSTRACTFive host-defense peptides (figainin 2PL, hylin PL, raniseptin PL, plasticin PL, and peptide YL) were isolated from norepinephrine-stimulated skin secretions of the banana tree dwelling frog Boana platanera (Hylidae; Hylinae) collected in Trinidad. Raniseptin PL (GVFDTVKKIGKAVGKFALGVAKNYLNS.NH2) and figainin 2PL (FLGTVLKLGKAIAKTVVPMLTNAMQP KQ.NH2) showed potent and rapid bactericidal activity against a range of clinically relevant Gram-positive and Gram-negative ESKAPE + pathogens and Clostridioides difficile. The...
Source: Biochimie - April 1, 2024 Category: Biochemistry Authors: J Michael Conlon Ananyaa Sridhar Dawood Khan Taylor S Cunning Jack J Delaney Megan G Taggart Nigel G Ternan J érôme Leprince Laurent Coquet Thierry Jouenne Samir Attoub Milena Mechkarska Source Type: research
The parallel lives of pandemics: COVID ‑19 and obesity
Exp Ther Med. 2024 Mar 6;27(5):184. doi: 10.3892/etm.2024.12472. eCollection 2024 May.ABSTRACTThe present article discusses the interconnectedness of coronavirus disease 2019 (COVID-19) and obesity as global health crises. The similarities between the two conditions are highlighted; these include shared risk factors and comorbidities, and the impact of obesity on the immune system. The present article also mentions the challenges faced in combating both pandemics, including misinformation and prejudice against obesity. It discusses the development of therapeutic medications and vaccines for COVID-19 and the potential of in...
Source: Experimental and Therapeutic Medicine - March 29, 2024 Category: General Medicine Authors: Vasiliki Epameinondas Georgakopoulou Ioannis G Lempesis Demetrios A Spandidos Source Type: research
